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Radiation-Induced Large Vessel Cerebral Vasculopathy in Pediatric Patients with Brain 
Tumors Treated with Proton Radiotherapy 
 
 
ABSTRACT 
PURPOSE: The purpose of this research is to evaluate the incidence, time to development, 
imaging patterns, risk factors, and clinical significance of large vessel cerebral vasculopathy in 
pediatric patients with brain tumors treated with proton radiotherapy.  
 
MATERIALS AND METHODS: A retrospective study was performed on 75 consecutive 
pediatric patients with primary brain tumors treated with proton radiotherapy. Radiation-induced 
large vessel cerebral vasculopathy (RLVCV) was defined as intracranial large vessel arterial 
stenosis or occlusion confirmed on MRA, CTA, and/or catheter angiography within an anatomic 
region with previous exposure to proton beam therapy and not present prior to radiotherapy. 
Clinical records were used to determine the incidence, timing, radiation dose to the large vessels, 
and clinical significance associated with the development of large vessel vasculopathy in these 
patients.  
 
RESULTS: RLVCV was present in 5/75 (6.7%) of patients and included tumor pathologies of 
craniopharyngioma (2), ATRT (1), medulloblastoma (1), and anaplastic astrocytoma (1). Median 
time from completion of radiotherapy to development was 1.5 years (mean 3.0 years; range 1.0-
7.5 years). Neither mean age at time of radiotherapy (5.1 years) nor mean radiotherapy dose to 
the large vessels (54.5 Gy) were statistically significant risk factors. Four of the five patients 
with RLVCV presented with acute stroke, and demonstrated MRI evidence of acute infarcts in 
the expected vascular distributions. Angiography studies demonstrated collateral vessel 
formation in only two of the patients with RLVCV. No patients demonstrated acute hemorrhage 
or aneurysm. Two patients were treated with pial synangiomatosis surgery.  
CONCLUSION: RLVCV can occur in pediatric patients with brain tumors treated with proton 
radiotherapy. Further studies are necessary to determine potential risk factors for large vessel 
vasculopathy with proton radiotherapy in comparison with conventional photon radiotherapy. 
 
 
Keywords: Proton radiotherapy; vasculopathy; pediatric; brain  
 
Abbreviations: ACA: anterior cerebral artery; ATRT: atypical teratoid rhabdoid tumor; CTA: 
CT Angiography; DWI: diffusion-weighted; FLAIR: fluid attenuated inversion recovery; GBM: 
glioblastoma multiforme; MCA: middle cerebral artery; MPRAGE: magnetization prepared 
rapid acquisition gradient echo; MRA: MR Angiography; PBT: proton beam radiotherapy; PCA: 
posterior cerebral artery; PNET: primitive neuroepithelial tumor; RLVCV: radiation induced 
large vessel cerebral vasculopathy; T1W: T1-weighted; T2W: T2-weighted; TSE: turbo spin 
echo   
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INTRODUCTION 
 
 
Radiotherapy is one of the primary therapies used to treat pediatric brain tumors. 
Potential adverse effects of radiotherapy on the brain include radiation necrosis, atrophy, gliosis, 
telangiectasia, cavernous malformations, and vasculopathy. Radiation-induced cerebral 
vasculopathy is relatively uncommon but has reported following conventional photon 
radiotherapy for pediatric brain tumors, most commonly gliomas, and medulloblastomas.1 
Radiation-induced vasculopathy histologically demonstrates subintimal foam cells and 
myointimal proliferation, fibrous thickening and hyalinization of the subintima, thickening of the 
elastica, fibrous thickening of the adventitia, and loose connective tissue thickening occluding 
the lumen.2 A correlation between radiation dose and age at radiotherapy with development of 
radiation-induced vasculopathy has been previously reported.1,3 Although radiation-induced 
vasculopathy can be diagnosed on histopathology, the diagnosis is primarily made by 
radiological evidence of arterial stenosis or occlusion of a large intracranial vessel that was 
previously normal prior to radiotherapy.   
Compared with conventional (photon) radiation therapy, proton beam radiotherapy (PBT) 
offers the advantages of the absence of an exit dose, a highly conformal dose distribution, and a 
reduced radiation dose to adjacent normal tissue.4  Therefore, potential benefits of PBT in 
patients with pediatric brain tumors may include the reduction of negative long-term effects of 
radiation, such as cognitive deficits, endocrine abnormalities, vascular abnormalities, and 
secondary malignancies.5 PBT has been used increasingly to treat pediatric brain tumors, 
including craniopharyngiomas, ependymomas, germinomas, and medulloblastomas; however, 
radiation-induced large vessel cerebral vasculopathy (RLVCV) has been reported in only a few 
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patients with PBT suggesting the complication is rare or yet to be fully evaluated in the 
literature.6-12  
Therefore, we evaluated the incidence, timing, imaging patterns, risk factors, and clinical 
significance of RLVCV in a cohort of pediatric patients with brain tumors treated with PBT.  
 
MATERIALS AND METHODS 
 
Following institutional review board approval, a retrospective study was performed from 
March 2007 to December 2014 on 75 pediatric patients age <18 with primary brain tumors who 
were treated with PBT and with radiation field covering the large intracranial arteries and who 
had clinical and MR imaging follow-up performed at our institution. Large cerebral arteries 
included the intracranial internal carotid artery (ICA), vertebral artery, basilar artery, middle 
cerebral artery (MCA) M1 segment, anterior cerebral artery (ACA) A1 segment, and posterior 
cerebral artery P1 segment.  All patients were either those with a newly diagnosed primary brain 
tumor who were subsequently treated with PBT or those who had low-grade gliomas without 
prior radiation therapy who demonstrated tumor progression on chemotherapy necessitating 
treatment with PBT. Patients were excluded if there was any history of treatment with photon 
radiation therapy, including before PBT, concurrent with PBT, or after PBT. Patients were also 
excluded if there was a prior course of PBT. Patients without at least 6 months of clinical follow-
up and MR imaging follow-up from the completion of PBT were excluded, including if death 
occurred before 6 months.  
PBT treatment doses followed the standard of care in the United States at a Children’s 
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Oncology Group treatment center with a continuum of radiation doses, the majority of patients 
receiving between 50 to 60 Gy total. The radiation oncologist (J.C.B.) approved 3D image 
guidance treatment plans before every single field in real-time for every patient. Typical target 
volumes with PBT included gross tumor volume (any visible residual tumor and/or resection 
cavity) to a clinical target volume (area of concern) margin of 5 mm; and the planning tumor 
volume (gross tumor volume plus clinical target volume) margin was set as 2 mm with a 5-mm 
margin when accounting for additional factors including smearing. All craniospinal radiation 
therapy was performed with PBT, not photon radiation therapy. The 3-D radiation dose 
distributions for each proton radiation plan were reviewed with attention to the relevant large 
intracranial vessels to confirm the large intracranial vessels were included in the radiation field 
and to determine the maximum radiation dose to the large intracranial arteries was recorded for 
all patients. In general, the median dose to the vertebral and basilar arteries were determined for 
posterior fossa tumors, and the median dose to the circle of Willis was calculated for 
supratentorial tumors.  
Brain MRI consisted of imaging performed with 1.5T or 3T (Avanto and Verio; Siemens, 
Erlangen, Germany) MR imaging units with axial and sagittal T1-weighted (T1W) turbo spin 
echo (TSE) or magnetization prepared rapid acquisition gradient echo (MPRAGE), axial T2-
weighted (T2W) TSE, axial fluid attenuated inversion recovery (FLAIR), axial diffusion-
weighted (DWI), coronal T1W TSE postcontrast with fat saturation, and axial 3D T1W 
MPRAGE post contrast pulse sequences. T1W MPRAGE sequences were performed at 1 mm 
slice thickness while other sequences were at 4 mm. Postcontrast imaging was performed in all 
patients after 0.1-mmol/kg intravenous administration of gadobenate dimeglumine (MultiHance; 
Bracco Diagnostics, Princeton, New Jersey). In the majority of patients, brain MRIs were 
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performed approximately every 1-3 months for 2-3 years, then every 6-12 months with shorter or 
longer follow-up depending on clinical need to assess tumor stability, clinical symptoms, and/or 
other complications of chemoradiation such as radiation necrosis. MR Angiography (MRA) of 
the brain, was performed with axial 3D time-of-flight technique with 0.7 mm slice thickness and 
with rotating maximum intensity projection images of the anterior and posterior circulation. CT 
angiography (CTA) of the brain was performed with Philips iCT 256 slice CT scanner (Philips, 
Best, Netherlands) with 0.9 mm slice thickness following administration of Isovue-370 (Bracco 
Diagnostics, Princeton, New Jersey) intravenous contrast and multi-planar reconstructions and 
maximum intensity projection images were performed in the coronal and sagittal planes. 
Catheter angiography was performed with Toshiba biplane (Toshiba Medical Systems, Tokyo, 
Japan) digital subtraction angiography with multiplanar views of the right and left internal and 
external carotid arteries and the vertebral arteries following intravenous contrast injection. 
Diagnosis of RLVCV was made if stenosis or occlusion of a large cerebral vessel was not 
present on imaging prior to PBT but developed on imaging following PBT, and was confirmed 
with either MRA, CTA, or catheter angiography. Diagnosis of RLVCV was not dependent on 
clinical manifestation of stroke. A fellowship-trained, board-certified neuroradiologist (S.F.K.) 
with certificate of added qualification in neuroradiology independently reviewed all MRIs, 
MRAs, CTAs, and catheter angiography studies before and after PBT.  Attention on all MRI 
studies was made to the large vessels on T2W and T1W post contrast MPRAGE sequences in all 
patients as a means to assess arterial stenosis. Assessment of arterial stenosis or occlusion was 
preformed by visual comparison to normal segments of the vessel or contralateral vessel when 
appropriate. When stenosis was present, the arterial stenosis was calculated based on the ratio of 
the arterial diameter of the narrowed segment to the arterial diameter of the normal proximal 
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segment and defined as mild for < 25% stenosis, moderate for 25-75% stenosis, and severe for > 
75% stenosis. Evidence of acute intracranial infarcts or hemorrhage on MRI, and aneurysm(s) on 
MRA, CTA, or catheter angiography were also recorded.  Clinical data obtained from the 
electronic medical record included patient age at time of PBT, patient gender, tumor pathology 
(with exception of some brainstem tumors which did not have pathology specimen), tumor 
location, total cranial radiation dose, timing from completion of PBT to imaging diagnosis of 
large vessel vasculopathy, treatment of vasculopathy, and clinical symptoms related to large 
vessel vasculopathy.  
Statistical analysis of clinical risk factors was performed by using a Fisher exact test and 
unpaired t test where appropriate. Statistics were performed using Graphpad Prism 7 Statistical 
Software (La Jolla, CA; http://www.graphpad.com; 2016) with p<0.05 considered statistically 
significant. A Kaplan-Meier curve for probability of not having RLVCV was calculated using 
Vassarstats (http://vassarstats.net) and probability with 95% confidence intervals (CI) were 
calculated. 
 
RESULTS 
 
Patient characteristics are listed in Table 1. A total of 5/75 (6.7%) of patients developed 
RLVCV. The median follow-up duration was 4.3 years (mean 4.2 years, range 0.6-9.6 years). 
Among the four patients with RLCVC, intracranial pathology consisted of craniopharyngioma 
(2), medulloblastoma (1), anaplastic astrocytoma (1), and ATRT (1). Representative examples of 
patients with RLCVC are seen in figures 1 and 2. The mean age at time of PBT for patients who 
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developed vasculopathy was 5.1 years compared to 8.0 years for patients without vasculopathy 
(p=0.17). The median time to development of large vessel vasculopathy was 1.5 years (mean 3.0 
years; range 1.0-7.5 years). A Kaplan Meier curve demonstrating the probability of development 
of RLVCV is seen in figure 3. The probability of not having RLVCV was 96% (88-99%, 
95%CI) at 3 years, 95% (86-98%, 95%CI) at 4 years, and 95% (85-98%, 95%CI) at 5 years. The 
mean radiation dose to the large cerebral arteries of patients at time of radiotherapy who 
developed vasculopathy was 54.5 Gy compared to 50.6 Gy for patients without vasculopathy 
(p=0.30).  
Prior to PBT, MRA was performed in five patients because the patient’s initial tumor 
presented as a hemorrhagic mass requiring assessment for an arteriovenous malformation. None 
of these MRAs demonstrated large intracranial artery stenosis. Prior to PBT, MRIs of the brain 
also did not demonstrate evidence of large intracranial artery stenosis except in one patient who 
had a suprasellar astrocytoma encasing the left ICA, MCA, and ACA that resulted in moderate 
arterial stenosis of these vessels.  
After PBT, eleven patients had MRA or CTA in conjunction with MRI, of which five 
were diagnosed with RLVCV based on presence of arterial stenosis. Details of patients with 
RLVCV are found in Table 2. Vasculopathy imaging findings included three patients with 
unilateral vasculopathy (left ICA occlusion; right ICA, MCA, and ACA stenosis; segmental 
basilar artery occlusion), and two patients with bilateral vasculopathy (bilateral vertebral artery 
stenosis; right ICA and left ACA stenosis).  Three of the the five patients had no visible 
collateral vessels on angiography studies. Four of the five patients presented clinically with acute 
stroke manifested as acute hemiparesis and had acute intracranial infarct(s) identified as MRI 
evidence of diffusion restriction in the distribution of the large vessel vasculopathy. Infarct 
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distribution pattern included two patients with MCA and ACA territory infarcts involving nearly 
the entire vascular territories, one patient with MCA territory infarct involving approximately 
25% of the MCA territory, and one patient with a unilateral pontine lacunar infarct involving less 
than 25% of the pons. The fifth patient who had a segmental occlusion of the basilar artery had 
chronic unilateral weakness which preceded radiation therapy and was attributed to the tumor 
involving the internal capsule and cerebral peduncle, but no clinical episode of stroke nor MRI 
evidence of acute or chronic infarct.  
Two patients had hypercoagulopathy laboratory testing with one patient demonstrating 
low anti-thrombin III and low protein C that was attributed to the acute phase of stroke, and one 
patient had high anti-thrombin III and low protein C. None of the patients had cholesterol 
laboratory testing. Two patients underwent pial synangiosis surgery. Three patients demonstrated 
residual hemiparesis of the affected side on last follow-up ranging from 26 months to 7 years. 
The patient with the pontine infarct was lost to follow-up. One patient died 26 months after the 
diagnosis of radiation-induced vasculopathy secondary to tumor recurrence. 
None of the patients with LVCV had acute intracranial hemorrhage, intracranial 
aneurysm, or neurofibromatosis type-1.  Among patients with LVCV, none were retrospectively 
identified on preceding MRI T2W or post contrast T1W MPRAGE sequences that were 
performed at a range of 2-6 months previously. Among patients without LVCV, none were 
identified to have clinically asymptomatic arterial stenosis on T2W or post contrast T1W 
MPRAGE.  
 
DISCUSSION 
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To our knowledge, this study is the largest series of RLVCV associated with PBT. In this 
study the crude incidence of RLVCV was approximately 6.7%, median time to development was 
1.5 years (mean 3.0 years; range 1-7.5 years), and median age at time of PBT was 5.1 years. In 
comparison, reported photon radiotherapy large vessel vasculopathy demonstrates median time 
to development of 5 years (range 0.3-27 years), and median age at time of radiotherapy of 4.83 
years.1  The incidence of vasculopathy in our study was less than that reported by Omura et al 
who reported large vessel vasculopathy in 6/32 (19%) of pediatric patients with primary brain 
tumors in whom photon radiation fields included the circle of Willis and large intracranial 
vessels although this study had median follow up duration of 5.2 years.3 Further studies are 
necessary to determine whether this difference in incidence reflects a reduction in large vessel 
vasculopathy with PBT compared to photon radiotherapy. At this time there is no reason to 
anticipate a difference in toxicity, including RLVCV, to normal tissues within a radiation 
treatment volume receiving a given dose, whether that dose was delivered by photon or PBT. We 
cannot assess whether the risk of RLVCV outside the target volume may be lower with PBT 
versus photon therapy, although the dose reduction to non-target tissues achieved by PBT may 
reduce the risk. 
The vasculature of pediatric patients is suspected to be more susceptible to effects of 
radiotherapy.13  In this study we are unable to demonstrate radiotherapy dose and age are risk 
factors for large vessel vasculopathy from PBT, although these results are likely due to the low 
incidence and our study may be helpful as more studies report results on radiation-induced 
vasculopathy with PBT. Omura et al performed a single institution evaluation of radiation 
induced large vessel vasculopathy and were able to demonstrate that increasing radiation dose 
was a risk factor but similarly could not determine if age was a risk factor, likely due to the low 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10 
incidence of large vessel vasculopathy at their single institution similar to our study.3  Wang et 
al, however, evaluated 77 reports of large vessel vasculopathy in pediatric patients with brain 
tumors treated with conventional radiotherapy and were able to demonstrate that younger age 
was a risk factor.1  We suspect that younger age and higher radiation dose remain risk factors for 
development of large vessel vasculopathy with PBT based on data from conventional 
radiotherapy, but further reports of patients with large vessel vasculopathy from PBT will be 
necessary to reach this conclusion.  
Radiation-induced vasculopathy has been reported to result in acute ischemic infarct, 
intraparenchymal hemorrhage, and aneurysm.14-18 This study demonstrates that a majority of 
patients with RLVCV will present with acute stroke, often with significant permanent 
neurological deficit, and may require surgical treatment to promote collateral vessel formation. 
Campen et al reported a 100-fold increase in risk of transient ischemic attack or stroke compared 
to the general population, a median time of 4.9 years from initial radiation to time of stroke, and 
an increased risk of stroke in patients with radiation therapy to the circle of Willis.14  Similarly, 
El-Fayech et al demonstrated that radiation doses of 10 Gy or more to the circle of Willis was 
associated with a cumulative stroke incidence of 11.3% compared to an expected incidence of 
1% in the general population.19 Our study, similar to other studies, is unable to determine what 
additional genetic or metabolic factors may contribute to the vasculopathy. Lastly, although 
RLVCV and radiation-induced Moyamoya are generally considered synonymous, we chose the 
term RLVCV rather than radiation-induced Moyamoya for purposes of consistency with the 
majority of the literature on this subject, and because the majority of these patients do not exhibit 
significant collateral vessel formation like patients with Moyamoya vasculopathy. The lack of 
extensive collateral vessel formation suggests the stenosis may progress more rapidly than 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11 
Moyamoya and likely accounts for the large areas of infarct encountered in some patients. This 
may also account for our inability to identify progressive stenosis occurring within the large 
arteries on MRIs prior to acute presentation of stroke and arterial stenosis or occlusion.  
As the number of PBT centers increases, it is important that physicians are aware of the 
potential for RLVCV in pediatric patients treated with PBT, particularly tumors near the circle of 
Willis. Neurological signs and symptoms of transient ischemic attacks may precede an acute 
stroke and may indicate need for vascular imaging in these patients. Although none of the 
patients demonstrated arterial stenosis on the MRI performed between 2-6 months preceding the 
diagnosis, we recommend that radiologists should still assess the intracranial vasculature on all 
patients treated with radiotherapy, particularly those tumors near the circle of Willis and 
recommend vascular imaging if there is suspicion of arterial stenosis on conventional MRI. It is 
uncertain if advanced imaging techniques such as MR perfusion or arterial wall imaging may 
help identify patients prior to development of arterial stenosis or be helpful to identify areas at 
risk for acute infarct.20 
 
LIMITATIONS: 
Because current clinical standard of care for these patients does not include routine 
performance of CTA, MRA, or catheter angiography, we acknowledge the potential limitation 
for determining the incidence and timing of RLVCV. Despite our efforts to review MRI 
sequences that best demonstrate the large intracranial arteries such as T2W and T1W post 
contrast MPRAGE, we were unable to identify large vessel stenosis on the MRIs obtained 
months in advance among patients with RLVCV who presented with acute stroke. Consequently, 
we are unable to conclude at this time that surveillance CTA or MRA should be performed in 
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these patients. Lastly, the RLVCV reported herein was not confirmed by histology, however, 
current clinical standard of care does not include arterial biopsy such that the diagnosis of 
RLVCV based on clinical and radiological data more closely reflects current clinical practice.  
Although this study represents the largest report of pediatric patients with RLVCV 
following PBT, this study represents a single institution experience and highlights the need for 
future investigations using multi-center collaboration with greater number of patients and 
expanded follow up duration to further understand the similarities and differences of PBT 
compared photon radiotherapy with respect to RLVCV. Incidence of RLVCV will likely be 
affected by follow up duration. In this research, our follow-up duration was approximately 4 
years which may still underestimate the incidence of RLVCV, however, we believe this does not 
detract from the importance of this research in building a foundation for additional research into 
RLVCV with proton radiotherapy and bringing greater clinical attention to this complication. 
Lastly, genetic and/or metabolic factors that may increase the risk of RLVCV to pediatric 
patients remain unknown and require further investigation.  
 
 
CONCLUSION 
 
 
Radiation-induced large vessel cerebral vasculopathy may occur in pediatric patients with 
brain tumors treated with PBT. With longer survival of pediatric patients with brain tumors, it is 
important for physicians to recognize the potential for RLVCV in pediatric patients with brain 
tumors treated with PBT. Further studies are necessary to advance the understanding of risk 
factors for development of RLVCV associated with PBT.  
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Figure 1. A 6-year-old with history of craniopharyngioma treated with proton radiotherapy. 
Sagittal T1W post contrast (A) image demonstrates the craniopharyngioma in the sella and 
suprasellar cistern (arrow) prior to radiotherapy. Sagittal radiation treatment image (B) 
demonstrate the dose lines of the proton beam treatment plan shown as percentages of the 
prescription dose (54 Gy). Axial DWI (C) image demonstrates a large region of hyperintensity in 
the right cerebral hemisphere consistent with an acute infarct involving the right ACA and MCA 
territories. Sagittal digital subtraction angiography (D) image following injection of the right 
ICA demonstrates severe stenosis of the right ICA (arrow) confirming the diagnosis of RLVCV. 
Digital subtraction angiography following injection of the left ICA (not shown) also 
demonstrated severe stenosis of the left ACA A1 segment with leptomeningeal collaterals 
providing retrograde filling of distal ACA branches. 
 
 
 
Figure 2.  An 18-month-old with history of ATRT treated with surgical resection, chemotherapy 
and proton radiotherapy. Axial DWI (A) image demonstrates a large region of hyperintensity 
consistent with an acute infarct in the left MCA distribution. Coronal CT Angiography (B) image 
demonstrates occlusion of the left supraclinoid ICA (arrow), decreased caliber of the left 
cavernous ICA segment, lack of filling of the left MCA, however both ACA vessels filling due 
to supply through the anterior communicating artery. Sagittal digital subtraction angiography (C) 
image following injection of the left ICA demonstrates severe stenosis at the origin of the 
posterior communicating artery and occlusion of the left ICA (arrow) just past the anterior 
choroidal artery, lack of filling of the left ACA and MCA vessels, and lack of lenticulostriate 
collateral vessels. 
 
 
Figure 3.  Kaplan-Meier curve demonstrating probability of radiation-induced large vessel 
cerebral vasculopathy over time. 
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Table 1: Patient Characteristics 
 
Category Characteristics 
Age Mean 7.9 years (range 1.5-18 years) 
Gender Male/Female 45:30 
Tumor Pathology Medulloblastoma/PNET 25 
 
Craniopharyngioma 14  
 
Pilocytic/Pilomyxoid astrocytoma 10  
 
Germinoma 6  
 
Brainstem glioma 6  
 
Ependymoma 4 
 
ATRT 3  
 
GBM/Anaplastic Astrocytoma 3 
 
Mature teratoma 2 
 
Pineoblastoma 1 
 
Pituitary adenoma 1 
Tumor Location Supratentorial 38  
- Sella/Suprasellar/Optic Pathway 24 
- Cerebral Hemisphere 7 
- Pineal 7 
 
Infratentorial 35 
-Cerebellar/4th ventricle 27 
-Brainstem 8 
 
Multifocal 2 
Total cranial radiation dose Mean 53.7 Gy (range 30-59.4 Gy) 
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Table 2: Description of pediatric patients with radiation-induced large vessel vasculopathy  
 
Patient 1 2 3 4 5 
Age at time 
of 
radiotherapy 
 
6 years 1.5 years 7 years 8 years 3 years 
Time to 
development  
 
3.8 years 1 year 7.5 years 1 year 1.5 years 
Radiation 
dose to large 
arteries 
54 Gy 54.6 Gy 55.8 Gy 54 Gy 54 Gy 
Pathology 
 
Craniopharyngioma ATRT Medulloblastoma Craniopharyngioma Anaplastic astrocytoma 
Location 
 
Sella and suprasellar 
cistern 
Multifocal 
supratentorial and 
infratentorial 
tumor foci 
Cerebellum Suprasellar cistern Multispatial: thalamus, 
right cerebral peduncle, 
optic chiasm, right temporal 
lobe 
Presentation 
 
Acute right MCA and 
right ACA infarct 
Acute left MCA 
infarct 
Acute pontine 
infarct 
Acute right MCA 
and ACA infarcts 
No acute or chronic infarct 
Vascular 
Imaging 
findings 
 
Right ICA stenosis 
(severe) and left ACA 
stenosis (severe); 
collateral vessels 
reconstitute the distal 
ACA and small number 
of collaterals from the 
right middle meningeal 
artery 
Left ICA 
occlusion, no 
collaterals 
Bilateral vertebral 
artery stenosis 
(moderate), no 
collaterals 
Right ICA, MCA, 
and ACA stenosis 
(severe), no 
collaterals 
Superior basilar artery 
occlusion with collaterals 
Treatment 
 
Bilateral pial 
synangiomatosis 
Left sided pial 
synangiomatosis 
None None None 
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SUMMARY: 
 
This is the largest study to report radiation-induced large vessel cerebral vasculopathy in 
pediatric patients with primary brain tumors treated with proton radiotherapy. This complication 
can lead to stroke and associated permanent neurological disability. This research adds to the 
relative limited knowledge of radiation-induced large vessel cerebral vasculopathy, establishes 
an estimate for the timing and incidence of this complication, and may be used in future research 
for comparison to conventional radiotherapy. 
 
